buprenorphine

Brand: Subutex, Suboxone (with naloxone), Buprenex, Belbuca, Butrans

⚠ BBW ISMP High Alert Prototype Drug

Drug Class: opioid partial agonist / analgesic

Drug Family: opioid

Subclass: partial mu-opioid agonist

Organ Systems: cns

Mechanism of Action

High-affinity partial agonist at mu-opioid receptors with a ceiling effect on respiratory depression; full kappa antagonist; very slow receptor dissociation (hours) creating long duration and precipitation of withdrawal if given to opioid-dependent patients; naloxone co-formulation (Suboxone) deters IV misuse.

mu-opioid receptors (partial agonist)kappa-opioid receptors (antagonist)

Indications

opioid use disorder (maintenance treatment)
moderate-to-severe chronic pain (Belbuca buccal film, Butrans patch)
opioid dependence induction

Contraindications

acute respiratory depression without resuscitation capability
severe hepatic impairment (IV Buprenex)

Adverse Effects

Common

headache
nausea
constipation
insomnia
diaphoresis
sublingual irritation

Serious

respiratory depression (occurs — ceiling effect reduces but does not eliminate risk, especially with CNS depressants)
precipitated withdrawal (if given to opioid-dependent patient before adequate washout)
QTc prolongation (high doses)
hepatotoxicity (elevated LFTs)

Pharmacokinetics (ADME)

Absorption	SL bioavailability ~30–50%; poor oral absorption due to first-pass; buccal ~46–65%
Distribution	Highly protein-bound (96%); Vd ~430 L; penetrates CNS well
Metabolism	CYP3A4 to active norbuprenorphine; then glucuronidation
Excretion	Fecal (~69%) and renal (~27%)
Half-life	24–42 hours
Onset	SL: 30–60 minutes
Peak	1–3 hours (SL)
Duration	24–72 hours
Protein Binding	96%
Vd	~430 L

Drug Interactions

Drug / Agent	Mechanism	Severity
benzodiazepines/CNS depressants	additive respiratory depression — FDA boxed warning	major
CYP3A4 inhibitors	increase buprenorphine levels	moderate
full opioid agonists	precipitates withdrawal due to high mu receptor affinity displacing opioids; must wait for adequate withdrawal before induction	major

Nursing Considerations

Buprenorphine induction: patient must be in mild-moderate opioid withdrawal (COWS score ≥8–12) before first dose to prevent precipitated withdrawal — this is the most critical nursing safety consideration
Suboxone (buprenorphine/naloxone): place film under tongue or in cheek until completely dissolved (2–10 min); do not swallow; eating and drinking should be avoided 30 minutes after
Monitor LFTs at baseline and periodically — hepatotoxicity has been reported; transient asymptomatic LFT elevation is common
Patient must be registered DEA-waivered provider (X-waiver, now integrated into DEA registration) to prescribe Suboxone for OUD; nursing assessment supports treatment adherence and monitoring

Clinical Pearls

Buprenorphine's ceiling effect on respiratory depression is a key safety advantage over full agonists — overdose fatalities are far less common with buprenorphine monotherapy than with methadone or full agonist opioids
The high mu receptor affinity of buprenorphine means it will displace other opioids from receptors — administering buprenorphine too early in an opioid-dependent patient precipitates severe acute withdrawal (precipitated withdrawal)

Safety Profile

Pregnancy safe

Lactation use-with-caution

Renal Adjustment Not required

Hepatic Adjustment Required

TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Moderate-to-severe Chronic Pain (Belbuca Buccal Film, Butrans Patch) Opioid Dependence Induction Opioid Partial Agonist / Analgesic Opioid Use Disorder (maintenance Treatment)

← Back to Medications